PER-062-13已完成未知
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATIO
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 17（—）
入选标准
- •1)For patients considered to be minors according to national legislation in each country, the written consent of the parent or legal guardian must be obtained, as well as the assent of the minor according to his or her capacity to understand the information provided. Patients within the specified age range who are not legally considered to be minors according to national legislation must consent in their own right. Patients enrolled as minors who attain legal adulthood during the course of the study must consent in their own right at that time.
- •2)Able and willing to comply with the study protocol
- •3)Age 12–17 years old at Visit 1 and Visit 3
- •4)Asthma diagnosis for ≥ 12 months prior to Visit 1
- •5)Bronchodilator response at Visits 1, 2, or 3
- •6)Pre-bronchodilator FEV1 of 40%–90% predicted at both Visits 2 and 3
- •7)On ICS therapy at a total daily dose of 500-2000 μg of fluticasone propionate DPI or equivalent ≥ 6 months prior to Visit 1 with no changes within 4 weeks prior to Visit 1 and no anticipated changes throughout the study.
- •8)On an eligible second controller medication (LABAs, LTRAs, LAMAs, or theophylline) for 6 months prior to Visit 1 with no changes within 4 weeks prior to Visit 1 and no anticipated changes throughout the study (except for theophylline dose, which may be adjusted on the basis of theophylline levels)
- •9)Uncontrolled asthma at Visit 1 and/or 2, and at Visit 3.
- •10)Demonstrated adherence with controller medication during the screening period.
排除标准
- •Patients who meet any of the following criteria will be excluded from study entry:
- •1)History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
- •2)Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid maintenance therapy within 3 months prior to Visit 1
- •3)Treatment with systemic corticosteroids within 4 weeks prior to Visit 1 or during the screening period for any reason, including an acute exacerbation event
- •4)Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
- •5)Infection that meets any of the following criteria:
- •-Any infection that resulted in hospital admission for ≥ 24 hours within 4 weeks prior to Visit 1 or during screening
- •-Any infection that required treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening
- •-Any active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening
- •-Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening
- •-Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
- •Antibiotics include any antimicrobial therapy used to treat bacterial, fungal, parasitic, viral or other infections. Antibiotics prescribed for prophylaxis should be discussed with the medical monitor
- •6)History of active tuberculosis requiring treatment
- •7. Known immunodeficiency, including, but not limited to, HIV infection
- •8. Evidence of acute or chronic hepatitis or known liver cirrhosis
研究者
相似试验
进行中（未招募）
1 期
A Study of Gantenerumab in Patients with Mild Alzheimer DiseaseEUCTR2013-003390-95-DKF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
1 期
A Study of Vemurafenib (RO5185426) in Comparison With Placebo as Adjuvant Therapy in Previously Untreated Patients With Adequately Resected Melanoma (BRIM 8)EUCTR2011-004011-24-ITF. HOFFMANN - LA ROCHE LTD.498
进行中（未招募）
1 期
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's diseaseEUCTR2014-003824-36-ATF. Hoffmann-La Roche Ltd1,150
尚未招募
3 期
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus trastuzumab emtansine versus placebo plus trastuzumab emtansine in patients with HER2-positive early breast cancer.CancerPACTR202201721209443Hoffmann La Roche1,700
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Breast cancerEUCTR2019-002455-42-FRF. Hoffmann-La Roche Ltd400